Amer Zeidan: It has been 16 years and 300 papers since my first paper was published in July 2007.

Amer Zeidan wrote in a recent tweet:

”It has been 16 years and 300 papers since my first paper was published in July 2007; how about you? Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy: Leukemia & Lymphoma: Vol 48, No 7.”

For the article click here
Source: Amer Zeidan/Twitter

Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.